Bio-Techne Launches a Simplified Brand Structure for Easier Access to Scientific Solutions
Bio-Techne Corporation, a global supplier of life science research tools, analytical technologies, and diagnostic solutions, has introduced a revised brand architecture intended to make its portfolio easier for scientists and clinicians to navigate. The new structure is designed around the practical stages of scientific work, helping customers identify relevant products more quickly based on their application, research focus, and development stage.
The company has consolidated its broad range of technologies into three dedicated portfolio brands: R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™. Together, these brands reflect the journey from early scientific discovery and translational research to clinical diagnostic development.
For five decades, Bio-Techne has supported scientific advancement through a diverse portfolio that includes proteins, antibodies, small molecules, immunoassays, protein analysis instruments, and spatial biology technologies. The updated brand framework brings these offerings into a more connected and accessible structure.
According to Bio-Techne President and CEO Kim Kelderman, the goal is to help researchers and healthcare professionals obtain clearer answers and move their work forward more efficiently. By organizing the portfolio around how research evolves, the company aims to reduce complexity and make the right solutions easier to find at every point in the scientific process.
The new identity also reinforces Bio-Techne’s role as a scientific partner focused on improving quality of life through progress in medicine, diagnostics, and life science research.
R&D Systems: Supporting Discovery-Stage Research
The R&D Systems portfolio combines Bio-Techne’s established selection of proteins, antibodies, immunoassays, small molecules, and research instruments. These tools are used by scientists around the world to conduct experiments, generate reproducible findings, confirm biological discoveries, and move promising research toward clinical use.
As the foundation of the research journey, R&D Systems provides dependable resources for exploring biological pathways and producing meaningful scientific evidence. The portfolio also includes GMP-grade materials and specialized reagents that support cell and gene therapy development workflows.
Bio-Techne Spatial: Advancing Translational Research
The Bio-Techne Spatial portfolio focuses on technologies that help researchers understand biology and disease within their original tissue context. It includes the established RNAscope™ in situ hybridization platform and the automated COMET™ spatial hyperplex platform.
These spatial biology solutions make it possible to visualize RNA and proteins with high resolution, sensitivity, and scalability. They also support multiomic analysis, helping researchers study cellular architecture, distinguish biologically important cell populations, identify clinically relevant biomarkers, and address pathology-led research questions.
By offering deeper insight into disease biology, Bio-Techne Spatial can help accelerate translational research and therapeutic discovery.
Bio-Techne Diagnostics: Enabling Reliable Diagnostic Assay Development
The Bio-Techne Diagnostics portfolio is designed for clinical laboratories and in vitro diagnostic (IVD) manufacturers. It includes assay kits, IVD-grade antibodies and reagents, molecular controls, calibrators, and proficiency-testing materials.
These products support diagnostic assay development across its full lifecycle—from early assay design and validation to scaled deployment. By supplying high-quality raw materials and complete assay-development solutions, Bio-Techne Diagnostics helps laboratories and manufacturers improve analytical reliability, strengthen clinical decision-making, and contribute to better patient care.
A Connected Route From Research to Clinical Application
Together, the three portfolio brands create a more consistent and end-to-end view of Bio-Techne’s capabilities. Customers can more easily connect the tools needed for basic research, translational studies, and diagnostic development, allowing scientific and clinical work to progress with greater clarity.
Bio-Techne plans to present its newly aligned portfolio at upcoming industry events, including the American Association for Cancer Research (AACR) Annual Meeting in San Diego and IMMUNOLOGY2026™ in Boston, United States.